Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Directive transparence : information réglementée

17/04/2024 07:00